224 related articles for article (PubMed ID: 26981780)
1. Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS.
Tavallai M; Booth L; Roberts JL; McGuire WP; Poklepovic A; Dent P
Oncotarget; 2016 Apr; 7(14):17290-300. PubMed ID: 26981780
[TBL] [Abstract][Full Text] [Related]
2. Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic.
Tavallai M; Booth L; Roberts JL; Poklepovic A; Dent P
Front Oncol; 2016; 6():142. PubMed ID: 27379204
[TBL] [Abstract][Full Text] [Related]
3. Regulation of dimethyl-fumarate toxicity by proteasome inhibitors.
Booth L; Cruickshanks N; Tavallai S; Roberts JL; Peery M; Poklepovic A; Dent P
Cancer Biol Ther; 2014; 15(12):1646-57. PubMed ID: 25482938
[TBL] [Abstract][Full Text] [Related]
4. Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma.
Ju W; Zhang M; Wilson KM; Petrus MN; Bamford RN; Zhang X; Guha R; Ferrer M; Thomas CJ; Waldmann TA
Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1624-9. PubMed ID: 26811457
[TBL] [Abstract][Full Text] [Related]
5. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
6. Fingolimod Augments Monomethylfumarate Killing of GBM Cells.
Dent P; Booth L; Roberts JL; Poklepovic A; Hancock JF
Front Oncol; 2020; 10():22. PubMed ID: 32047722
[TBL] [Abstract][Full Text] [Related]
7. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
[TBL] [Abstract][Full Text] [Related]
8. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
Booth L; Roberts JL; Samuel P; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Jun; 19(6):525-533. PubMed ID: 29405820
[TBL] [Abstract][Full Text] [Related]
9. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
[TBL] [Abstract][Full Text] [Related]
10. Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
Taverna JA; Hung CN; DeArmond DT; Chen M; Lin CL; Osmulski PA; Gaczynska ME; Wang CM; Lucio ND; Chou CW; Chen CL; Nazarullah A; Lampkin SR; Qiu L; Bearss DJ; Warner S; Whatcott CJ; Mouritsen L; Wade M; Weitman S; Mesa RA; Kirma NB; Chao WT; Huang TH
Cancer Res; 2020 Apr; 80(7):1551-1563. PubMed ID: 31992541
[TBL] [Abstract][Full Text] [Related]
11. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells.
Yacoub A; Park MA; Hanna D; Hong Y; Mitchell C; Pandya AP; Harada H; Powis G; Chen CS; Koumenis C; Grant S; Dent P
Mol Pharmacol; 2006 Aug; 70(2):589-603. PubMed ID: 16622074
[TBL] [Abstract][Full Text] [Related]
12. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
13. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
Rahmani M; Aust MM; Benson EC; Wallace L; Friedberg J; Grant S
Clin Cancer Res; 2014 Sep; 20(18):4849-60. PubMed ID: 25070836
[TBL] [Abstract][Full Text] [Related]
14. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
[TBL] [Abstract][Full Text] [Related]
15. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
[TBL] [Abstract][Full Text] [Related]
16. The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
Mazzacurati L; Collins RJ; Pandey G; Lambert-Showers QT; Amin NE; Zhang L; Stubbs MC; Epling-Burnette PK; Koblish HK; Reuther GW
Blood Adv; 2019 Nov; 3(22):3503-3514. PubMed ID: 31725895
[TBL] [Abstract][Full Text] [Related]
17. Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination.
Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
Apoptosis; 2020 Jun; 25(5-6):370-387. PubMed ID: 32394008
[TBL] [Abstract][Full Text] [Related]
18. Dimethyl fumarate and monomethyl fumarate attenuate oxidative stress and mitochondrial alterations leading to oxiapoptophagy in 158N murine oligodendrocytes treated with 7β-hydroxycholesterol.
Sghaier R; Nury T; Leoni V; Caccia C; Pais De Barros JP; Cherif A; Vejux A; Moreau T; Limem K; Samadi M; Mackrill JJ; Masmoudi AS; Lizard G; Zarrouk A
J Steroid Biochem Mol Biol; 2019 Nov; 194():105432. PubMed ID: 31344443
[TBL] [Abstract][Full Text] [Related]
19. Pro-Apoptotic Activity of Ruxolitinib Alone and in Combination with Hydroxyurea, Busulphan, and PI3K/mTOR Inhibitors in JAK2-Positive Human Cell Lines.
Szymańska J; Smolewski P; Majchrzak A; Cebula-Obrzut B; Chojnowski K; Treliński J
Adv Clin Exp Med; 2015; 24(2):195-202. PubMed ID: 25931349
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Mitchell C; Yacoub A; Hossein H; Martin AP; Bareford MD; Eulitt P; Yang C; Nephew KP; Dent P
Cancer Biol Ther; 2010 Nov; 10(9):903-17. PubMed ID: 20855960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]